Aimovig (erenumab-aooe) was the first CGRP monoclonal antibody the FDA approved for migraine prevention, in 2018, and it is co-developed by Amgen and Novartis. In the United States it is a once-monthly SureClick autoinjector, sold in 70 mg and 140 mg strengths, with no generic and no biosimilar.
For a cash payer, Aimovig is the most interesting drug in its class right now, because Amgen has done something none of its competitors quite matches: it publishes its list price openly and it also underwrites a flat cash price that is well under a third of it. This guide prices every route as verified on September 2, 2026, using Amgen’s own list-pricing document, a state price-disclosure filing, two federal CMS datasets, a live pharmacy page and the foundation’s own application form. Costs and logistics only, no medical advice.
What Does Aimovig Cost Without Insurance?
All figures are per month, which is one SureClick autoinjector at either strength. Verified September 2, 2026.
| Route | Low | Typical | High |
|---|---|---|---|
| Amgen list price (WAC), 70 mg or 140 mg pen | $783.02 | $783.02 | $783.02 |
| Average retail cash price (SingleCare) | $1,057.88 | $1,057.88 | $1,057.88 |
| Named-chain retail cash price | $924.99 | $944.99 | $1,437.76 |
| Amgen cash-pay program price (via GoodRx) | $299.00 | $299.00 | $299.00 |
| SingleCare discount-card price | $767.79 | $812.43 | $949.02 |
| Pharmacy acquisition cost (CMS NADAC) | $753.38 | $753.58 | $753.58 |
| Aimovig Co-Pay Card (commercial insurance only) | $49.00 | $49.00 | $49.00 |
| Amgen Safety Net Foundation (income-qualified) | $0 | $0 | $0 |
Two sources agree on the list price to the cent. The Aimovig list-pricing document that Amgen links from aimovig.com states a current wholesale acquisition cost of $783.02 per syringe for both NDC 55513-0841-01 (70 mg/mL) and NDC 55513-0843-01 (140 mg/mL), accurate as of January 7, 2026. The Texas Department of State Health Services 2026 Annual WAC Report, which collects manufacturer-reported January 1, 2026 list prices, shows Amgen USA reporting $783.02 for both of those same NDCs.
CMS’s National Average Drug Acquisition Cost file, effective August 19, 2026, puts what pharmacies pay at $753.58 for the 70 mg pen and $753.38 for the 140 mg pen, about 96% of list. That is the floor beneath any pharmacy’s cash price, and it is what makes the $299 program notable: it is priced far below what the pharmacy paid for the box, which only a manufacturer subsidy can do.
Retail figures come from SingleCare’s live Aimovig page, updated September 2, 2026: an average retail price of $1,057.88 for a 140 mg pen, named-chain retail from $924.99 to $1,437.76, and card prices from $767.79 to $949.02. Those chain-level numbers move between visits, so read them as a picture of the spread rather than as prices you can hold anyone to.
What Drives the Price
Strength does not change the price. Amgen charges the same $783.02 for 70 mg and 140 mg. Whichever dose your prescriber lands on, the monthly cost is identical, which is unusual and worth knowing before you assume the lower dose is the cheaper one.
Whether you use the manufacturer’s cash channel. This is the whole ballgame. At the counter with no help, Aimovig averages $1,057.88. Through Amgen’s cash-pay program it is $299.00. That is a difference of about $9,100 a year on the same box of medicine.
No generic, no biosimilar. Erenumab is a biologic. The NADAC file lists a corresponding generic acquisition cost whenever one exists, and every Aimovig row leaves that field blank as of August 19, 2026. There is no cheap copy to wait for.
Specialty pharmacy routing. CGRP injectables are often filled through specialty pharmacies. That is a large part of why the named-chain spread on a single discount page ran from $924.99 to $1,437.76 for the same product on the same day. Calling two or three pharmacies is not paranoia, it is the actual price-discovery mechanism.
Program terms can change. The $299 price is a manufacturer-sponsored offer, not a regulated price. It carried Amgen’s job code on the page we read on September 2, 2026, and offers like this get amended or withdrawn. Confirm it before you build a year’s budget on it.
Cash Price vs. Insurance
For Aimovig, the ranking is unusual: good commercial insurance still wins, but paying cash the smart way now beats what Medicare pays.
CMS’s Medicare Part D Spending by Drug dashboard, published June 2026 with 2024 data, shows the program paid an average of $904.56 per Aimovig claim and $726.51 per dosage unit, across 55,791 beneficiaries and about $305.6 million in total 2024 spending. A cash payer using the $299 program is paying roughly a third of the average Part D claim.
If you have commercial insurance that covers Aimovig, the co-pay card takes eligible patients to as little as $49 a month, which still beats $299. But Amgen’s own page restricts that card to patients covered by private or commercial insurance, and it sends uninsured readers somewhere else entirely: to Amgen SupportPlus, which provides information about independent nonprofit foundations. Notably, aimovig.com does not itself mention the Amgen Safety Net Foundation on that page, even though the foundation does supply Aimovig free. If you are uninsured, ask about the foundation by name.
The usual caveat applies. Paying cash means the spend does not count toward a deductible or an out-of-pocket maximum. On a high-deductible plan in a year when you expect large medical bills, running the claim can be the better annual decision even when the cash price looks better this month.
How to Pay Less
Use the $299 cash-pay program. Amgen’s cash-pay option showed $299.00 a month at every pharmacy listed on September 2, 2026, against $944.99 without it. You do not need insurance to use it, and the disclosure states plainly that it is for people without insurance or who prefer to pay out of pocket. Bring the coupon to the pharmacy before the prescription is run, not after.
Apply to the Amgen Safety Net Foundation if you qualify. The July 2026 Aimovig application sets three requirements: six months or longer living in the U.S. or its territories, no insurance coverage, and household income at or below $47,880 for one person or $64,920 for two, adding $17,040 for each additional person. Approved patients pay nothing, and the foundation states it never charges a fee, so any organization billing you monthly for “help” with it is not the foundation.
Still check the discount cards. They are not the best route here, but they are the fallback if the manufacturer program is unavailable to you. SingleCare’s card price on September 2, 2026 was $767.79 against an average retail price of $1,057.88. Our GoodRx vs. SingleCare comparison covers how to price both quickly, and because these numbers are recalculated constantly, re-check at every refill.
Compare the class, because the cash routes differ more than the prices do. At list, the four self-injected CGRP preventives sit within about $30 a month of each other, but what an uninsured person actually pays does not. Emgality is sold direct by LillyDirect starting at $299 a month, Ajovy has no manufacturer cash price at all and bottoms out near $690 with a card, and Vyepti is a clinic infusion billed as a medical claim.
Trim the acute side of the budget too. Preventives are only part of migraine spending. Generic sumatriptan costs a small fraction of the branded rescue options like Nurtec, Ubrelvy and Qulipta.
Price the visit separately from the drug. The appointment that produces the prescription generates its own bill. Check a reasonable cash consult price with our fair price checker, ask a hospital-owned neurology clinic about charity care before you go, and if a bill has already landed, our guide to negotiating medical bills has the scripts.
The Bottom Line
Aimovig lists at $783.02 a month as of January 2026 and averages about $1,058 at a retail counter with no help. Neither of those is the number an uninsured reader should pay. Amgen’s cash-pay program prices it at $299 a month, and the Amgen Safety Net Foundation supplies it free below $47,880 in household income for one person.
The mistake to avoid is assuming the widely advertised $49 co-pay card applies to you. It does not without commercial insurance. The $299 program is the one built for cash payers, and at roughly $3,588 a year it is the cheapest reliable route to a CGRP preventive we found in September 2026.